Tenaya Therapeutics (TNYA) Equity Average (2020 - 2026)

Tenaya Therapeutics has reported Equity Average for 7 years, with the latest figure at $114.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 8.11% year-over-year to $114.7 million; the trailing twelve-month figure through Mar 2026 stood at $114.7 million (up 8.11% YoY), and the FY2025 full-year result was $108.1 million, down 6.96% from the prior year.
• Equity Average for Q1 2026 stood at $114.7 million, up from $103.1 million in the prior quarter.
• The five-year high for Equity Average was $263.8 million in Q1 2022, with the low at $91.3 million in Q3 2025.
• Average Equity Average over 5 years is $161.0 million, with a median of $148.8 million recorded in 2024.
• Year-over-year, Equity Average soared 401.06% in 2022 and plunged 35.13% in 2024.
• Tracing TNYA's Equity Average over 5 years: stood at $219.9 million in 2022, then slumped by 30.79% to $152.2 million in 2023, then plunged by 32.48% to $102.7 million in 2024, then grew by 0.33% to $103.1 million in 2025, then gained by 11.31% to $114.7 million in 2026.
• The last three Equity Average figures came in at $114.7 million (Q1 2026), $103.1 million (Q4 2025), and $91.3 million (Q3 2025), per Business Quant data.

Peer Comparison